Aktis Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKTS research report →
Range $35 – $40
Price Chart
About the company
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes.
- CEO
- Matthew Roden
- IPO
- 2026
- Employees
- 79
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on AKTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $868.01M
- P/E
- -10.16
- PEG
- 0.69
- P/S
- 70.08
- P/B
- 1.96
- EV/EBITDA
- -8.63
- Div Yield
- 0.00%
- Gross Margin
- 80.03%
- Op Margin
- -837.45%
- Net Margin
- -706.81%
- ROE
- -26.86%
- ROIC
- -20.80%
Latest fiscal year · YoY change
- Revenue
- $6.50M+336.9%
- Gross Profit
- $6.50M+336.9%
- Op Income
- $-74,684,000
- Net Income
- $-63,731,000-44.9%
- EPS
- $-1.19+5.6%
- OCF Growth
- -534.4%
- FCF Growth
- -719.4%
- 52W High
- $34.19
- 52W Low
- $13.96
- 50D MA
- $17.84
- 200D MA
- $20.69
- Beta
- 0.45
- RSI (14)
- 48
- Avg Volume
- 406.14K
No earnings-call transcripts are available for AKTS yet.
- Free Float
- 53.0%
- Shares Outstanding
- 53.75M
- Float Shares
- 28.49M
of shares held by institutions
116 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mpm Bioimpact LLC | 4.84M | 0 |
| Ecor1 Capital, LLC | 4.82M | 0 |
| Blue Owl Capital Holdings LP | 3.34M | ▲ 273.61K |
| Blackrock, Inc. | 2.78M | ▲ 502.39K |
| T. Rowe Price Investment Management, Inc. | 2.05M | ▼ 72.36K |
| Wellington Management Group Llp | 1.97M | ▼ 350.80K |
| Rtw Investments, LP | 1.59M | 0 |
| Janus Henderson Group Ltd. | 1.45M | ▲ 1.45M |
| Ra Capital Management, L.P. | 1.31M | ▼ 188.68K |
| Jupiter Topco LLC | 1.31M | ▲ 1.31M |
| Vanguard Capital Management LLC | 1.18M | ▲ 363.85K |
| Eventide Asset Management, LLC | 1.06M | ▲ 558.00K |
Held by 141 ETFs
Biggest fund positions in AKTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Feldman Paul L | other | 55,035 |
| Nov 18, 26 | Feldman Paul L | other | 55,035 |
| Sep 23, 26 | Czibere Akos | other | 12,500 |
| Sep 23, 26 | Czibere Akos | other | 12,500 |
| Sep 23, 26 | Czibere Akos | sell | 5,099 |
| Sep 23, 26 | Czibere Akos | sell | 7,401 |
| Jul 20, 26 | Herrmann Ken | other | 1,350 |
| Jul 20, 26 | Herrmann Ken | other | 1,350 |
| Jul 20, 26 | Herrmann Ken | other | 3,506 |
| Jul 20, 26 | Herrmann Ken | sell | 3,506 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AKTS coverage
Recent articles, reports, and earnings notes.
No research on AKTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKTS report →Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress
globenewswire.com · Nov 12
Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?
zacks.com · Nov 11
Aktis Oncology: Padcev Is Building The Market It Wants
seekingalpha.com · Oct 14
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
globenewswire.com · Oct 1
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
investopedia.com · Aug 14
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
globenewswire.com · Aug 13
Aktis Oncology: Mini-Proteins With A Targeted Punch
seekingalpha.com · Jun 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.